Results 81 to 90 of about 854 (146)

Migraine history and response to lasmiditan across racial and ethnic groups

, 2022
The robust enrollment in SPARTAN and SAMURAI provided the opportunity to present post-hoc descriptive details on migraine disease characteristics and treatment outcomes after treatment with lasmiditan, a selective serotonin (5-HT1F) receptor agonist, in ...
Simin K. Baygani (9465062), Ellen B. Dennehy (3344684), Larry Charleston IV (12320543), Belinda Savage-Edwards (12320546), Sonja M. Bragg (12340545)   +4 more
core   +1 more source

Preclinical pharmacological profile of the selective 5-HT_1F receptor agonist lasmiditan

, 2010
Introduction: Lasmiditan (also known as COL-144 and LY573144; 2,4,6-trifluoro- N-[6-[(1-methylpiperidin-4-yl)carbonyl]pyridin-2yl]benzamide) is a high-affinity, highly selective serotonin (5-HT) 5-HT1F receptor agonist.
David L Nelson, Marlene L Cohen, Kirk W Johnson, David B Wainscott, David O Calligaro, Lee A Phebus, Yao-Chang Xu   +6 more
core   +1 more source

Evaluating and comparing the safety and efficacy of rimegepant versus lasmiditan in aborting acute migraine headaches in the adult migraineur [PDF]

, 2023
Migraine headaches are one of the most common causes of primary headaches and one of the leading causes of disability worldwide. While the mechanism of migraines are not entirely understood, they can result in significant disability (DynaMed, 2023 ...
Douthit, Anthony
core  

Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review

Drug, Healthcare and Patient Safety, 2021
Flavia Lo Castro,1 Simona Guerzoni,1 Lanfranco Pellesi2 1Medical Toxicology, Headache and Drug Abuse Research Center, Department of Specialized Medicine, AOU Policlinico di Modena, Modena, Italy; 2Danish Headache Center, Department of Neurology ...
Lo Castro F, Guerzoni S, Pellesi L
doaj  

Acute treatment of migraine with the selective 5-HTIF receptor agonist lasmiditan - A randomised proof-of-concept trial

, 2010
Introduction: Lasmiditan (COL-144; LY573144) is a novel, highly selective and potent agonist at 5-HTIF receptors that lacks vasoconstrictor activity.
Alison Pilgrim, Martin Krauss, Ferrari, M.D., Farkkila, M., Markus Färkkilä, null null, Pilgrim, A., Diener, H.C., Davis, C., Reuter, U., European COL-144 Investigators, Charles Davis, Hans-Christoph Diener, Krauss, M., Michel D Ferrari, Uwe Reuter   +15 more
core   +1 more source

Additional file 2: of Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

, 2019
Table S2. Treatment-emergent adverse events occurred at similar rates in patients using and not using migraine preventive treatments for all doses of lasmiditan.
Jack Schim (7039022), Li Loo (7039016), John Krege (7039034), Jessica Ailani (7039019), Hans-Peter Hundemer (7039028), Martha Port (7039031), Simin Baygani (7039025)   +6 more
core   +1 more source

Additional file 1: of Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials

, 2019
Table S1. Odds ratios for lasmiditan treatment versus placebo were similar or greater in the group of patients using topiramate and propranolol.
Jack Schim (7039022), Li Loo (7039016), John Krege (7039034), Jessica Ailani (7039019), Hans-Peter Hundemer (7039028), Martha Port (7039031), Simin Baygani (7039025)   +6 more
core   +1 more source

CEP889350 Supplemetal Material5 - Supplemental material for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans

, 2019
Supplemental material, CEP889350 Supplemetal Material5 for Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans by Kerry Knievel, Andrew S Buchanan, Louise Lombard, Simin Baygani, Joel Raskin, John H Krege, Li ...
Li Shen Loo (7905155), Louise Lombard (6813860), Mika Komori (114112), Andrew S Buchanan (7905152), John H Krege (7875398), Joel Raskin (7875404), Kerry Knievel (7905149), Joshua Tobin (7905158), Simin Baygani (7039025)   +8 more
core   +1 more source

Menstrual migraine. Diagnosis, pathogenesis and review of acute and short-term prevention pharmacotherapy

Journal of Education, Health and Sport
Background Menstrual migraine describes migraines that occur in alignment with the menstrual cycle, affecting women of diverse age ranges. This condition is relatively common, presenting a unique challenge due to the heightened intensity of pain ...
Daria Furtak, Wiktor Grela, Jagoda Niewiadomska, Dawid Tulej, Paulina Głogowska, Alicja Dziedzic, Natalia Gniaź, Dominika Marciniuk, Natalia Marko, Aleksandra Górska   +9 more
doaj   +1 more source

ePoster

European Journal of Neurology, Volume 33, Issue S1, June 2026.
wiley   +1 more source